Basecamp Wealth Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Basecamp Wealth Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-287	Closed	-$15.1K	–	1980
2026 Q1	$15.1K	Buy	287 +147	+105%	+$6.04K	﹤0.01%	905
2025 Q4	$5.66K	Buy	+140	New	+$3.23K	﹤0.01%	1122

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Basecamp Wealth Advisors's TERN Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 287 shares — an estimated $15.1K sold.

Basecamp Wealth Advisors first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $15.1K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Basecamp Wealth Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 287 Terns Pharmaceuticals shares in Q2 2026, an estimated $15.1K.
Basecamp Wealth Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Basecamp Wealth Advisors's Terns Pharmaceuticals position peaked at $15.1K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.